Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of tumour infiltrating lymphocytes in patients with metastatic melanoma

Trial Profile

Phase II trial of tumour infiltrating lymphocytes in patients with metastatic melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lifileucel (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics; Lion Biotechnologies Inc
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 16 Sep 2015 According to a Lion Biotechnologies media release, updated results from this trial were presented at the American Association for Cancer Research Inaugural International Cancer Immunotherapy Conference.
    • 16 Sep 2015 Updated results from this trial were published in a Lion Biotechnologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top